查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1405963

小分子CDMO市场规模、份额和趋势分析报告：按产品、药物类型、应用、地区和细分市场预测，2024-2030年

Small Molecule CDMO Market Size, Share & Trends Analysis Report By Drug Type (Generics, Innovators), By Product (APIs, Finished Drug Products), By Application (Oncology, CVD, CNS Conditions), By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 180 Pages | 商品交期: 2-10个工作天内

价格

小分子 CDMO 市场成长与趋势：

Grand View Research, Inc.的最新研究显示，预计2030年全球小分子CDMO市场规模将达到1,084.6亿美元，2024年至2030年复合年增长率为7.1%。

开发小分子药物开发创新技术，以小分子治疗药物为重点拓展药物管线，并依托CDMO（合约药物开发和受託製造厂商）提供具有成本效益的专业製造服务。需求不断增长，法律规范支持高效药物开发和製造流程以及 CDMO 扩大製造能力以满足行业需求是支持市场成长的一些因素。创新和轻鬆进入诊所是製药公司的重要因素。

小型企业和专业製药公司越来越依赖满足行业内的这些关键要求。许多 CDMO 将自己定位为一站式服务公司。一站式服务模式意味着 CDMO 提供从原料药(API) 到剂型、从早期开发到商业化的一切服务。为了提供此类服务，CDMO 必须拥有广泛的实行技术和专门的处理能力来解决特定的问题说明。全球范围内大量提供全面研究、开发和製造服务的 CDMO 预计将支持市场成长。慢性病的高盛行率也是支持新型小分子疗法开发的主要因素，推动了对 CDMO 服务的需求。

国际糖尿病联盟（IDF）表示，该国糖尿病盛行率正在逐渐上升。报告称，2022年中国将有超过1.4亿人被诊断为糖尿病，2030年将有1.744亿人被诊断为糖尿病。摄取大量不健康脂肪和久坐的生活方式是导致糖尿病发生率增加的主要因素。糖尿病负担的增加预计将推动该国对 CDMO 服务的需求。对药品研发的大量投资是产业成长的关键驱动力。随着製药公司专注于发现和开发小分子疗法，对 CDMO 服务的需求也在增加。这些服务对于小分子药物的高效且经济高效的开发和製造至关重要。

小分子 CDMO 市场报告亮点

  • 由于开发新药的倡议措施增加，原料药细分市场在 2023 年占最大份额，达到 62.3%。大型製药企业强大的药品管道也支持该行业的成长。
  • 预计 2024 年至 2030 年，学名药领域的复合年增长率将达到 8.0%，是最高的。癌症、糖尿病和心血管疾病（CVD）等疾病的沉重负担以及政府为改善学名药的获取而做出的努力是促进该行业增长的主要因素。
  • 由于全球癌症患者数量的增加，2023年肿瘤领域的销售额份额最高，达35.1%。此外，更强有力的政府报销政策和对小分子癌症药物开发的资金筹措增加预计将支持该行业的成长。
  • 预计 2024 年至 2030 年，亚太地区复合年增长率最高，为 7.7%。亚太地区，尤其是中国和印度，由于製造成本显着低于北美和欧洲且法律更完善，仍然是主导的区域市场。

目录

第一章调查方法和范围

第 2 章执行摘要

第三章小分子 CDMO 市场变数、趋势与范围

  • 市场体系展望
    • 母市场展望
    • 相关/附随市场展望
  • 市场动态
    • 市场驱动因素分析
    • 市场抑制因素分析
  • 小分子CDMO市场分析工具
    • 产业分析-波特五力分析
    • PESTEL分析

第四章小分子CDMO市场：产品预估及趋势分析

  • 定义和范围
  • 2023年及2030年产品市场占有率
  • 细分仪表板
  • 按产品分類的全球小分子 CDMO 市场展望
  • 2018年至2030年市场规模、预测与趋势分析
    • 活性药物成分 (API)
    • 医药成品

第五章 小分子CDMO市场：药物类型预估及趋势分析

  • 定义和范围
  • 2023 年和 2030 年药物类型市场占有率
  • 细分仪表板
  • 按药物类型分類的全球小分子 CDMO 市场展望
  • 2018年至2030年市场规模、预测与趋势分析
    • 创新者
    • 非专利的

第六章 小分子CDMO市场：应用预估与趋势分析

  • 定义和范围
  • 2023年及2030年应用市场占有率
  • 细分仪表板
  • 全球小分子CDMO市场按应用前景展望
  • 2018年至2030年市场规模、预测与趋势分析
    • 瘤
    • 循环系统疾病
    • 中枢神经系统 (CNS) 疾病
    • 自体免疫/发炎
    • 其他的

第七章小分子CDMO市场：区域估计与趋势分析

  • 2023 年及 2030 年区域市场占有率分析
  • 区域市场仪表板
  • 全球区域市场概述
  • 北美洲
    • 2018-2030 年市场估计与预测
    • 美国
    • 加拿大
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 丹麦
    • 瑞典
    • 挪威
  • 亚太地区
    • 日本
    • 印度
    • 中国
    • 韩国
    • 澳洲
    • 泰国
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
  • 中东/非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第八章竞争形势

  • 市场参与企业分类
    • 创新者
    • 市场领导者
    • 新兴玩家
    • 2023 年公司市场占有率分析
  • 公司简介
    • Lonza
    • Catalent, Inc
    • Thermo Fisher Scientific Inc.
    • Cambrex Corporation
    • Bellen Chemistry
    • Siegfried Holding AG
    • Recipharm AB
    • Eurofins Scientific
    • Aurigene Pharmaceutical Services Ltd.
    • CordenPharma International
Product Code: GVR-4-68040-165-6

Small Molecule CDMO Market Growth & Trends:

The global small molecule CDMO market size is expected to reach USD 108.46 billion by 2030, registering a CAGR of 7.1% from 2024 to 2030, according to a new study by Grand View Research, Inc. Exploration of innovative technologies in small molecule drug development, expansion of pharmaceutical pipelines with a focus on small molecule therapeutics, growing reliance on contract development and manufacturing organizations (CDMOs) for cost-effective and specialized manufacturing services, regulatory frameworks supporting efficient drug development & manufacturing processes, and CDMOs expanding manufacturing capacities to meet industry demands are few of the factors supporting market growth. For pharmaceutical companies, innovation and easy access to clinics are critical factors.

Small-scale companies and specialty pharmaceutical players increasingly rely on delivering these important requirements within the industry. Many CDMOs establish themselves as one-stop-shop companies. The one-stop-shop service model is where a CDMO offers everything, from active pharmaceutical ingredient (API) to dosage form and early development to commercialization. To provide these services, a CDMO must have a wide range of enabling technologies and specialized handling capabilities that help address specific problem statements. A significant number of CDMOs across the globe providing all research, development, and manufacturing services is expected to support market growth. The high prevalence of chronic ailments is another considerable factor supporting the development of novel small molecule-based therapeutics, thus boosting CDMO services demand.

The International Diabetes Federation (IDF) states that the incidence of diabetes is rising gradually in the country. It states that in 2022, over 140 million people in China had diabetes, and 174.4 million are expected to be diagnosed by 2030. High consumption of unhealthy fats and a sedentary lifestyle are major factors contributing to the high incidence of diabetes. The growing burden of diabetes is expected to drive CDMO services demand in the country. Substantial investment in pharmaceutical R&D is a significant driver bolstering industry growth. As pharmaceutical companies intensify their efforts in discovering & developing small molecule therapeutics, there is a corresponding rise in demand for CDMO services. These services are crucial in the efficient & cost-effective development & manufacturing of small-molecule drugs.

Small Molecule CDMO Market Report Highlights:

  • The API segment accounted for the largest share of 62.3% in 2023 due to increased R&D initiatives for novel medicine development. The robust drug pipelines of major pharmaceutical players also propel segment growth
  • The generics drug type segment is anticipated to have the highest CAGR of 8.0% from 2024 to 2030. The high burden of diseases, such as cancer, diabetes, and cardiovascular disorders (CVDs), and initiatives by the governments to improve access to generic drugs are the key factors contributing to segment growth
  • The oncology segment held the highest revenue share of 35.1% in 2023 owing to an increasing number of cancer cases globally. Furthermore, increased government reimbursement policies and a rise in financing for developing small molecule oncology therapies are expected to boost segment growth
  • Asia Pacific is anticipated to witness the highest CAGR of 7.7% from 2024 to 2030. Due to significantly cheaper manufacturing costs than North America & Europe and favorable laws, Asia Pacific, particularly China & India, has remained the dominant regional market

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
    • 1.1.1. Product
    • 1.1.2. Drug Type
    • 1.1.3. Application
    • 1.1.4. Regional scope
    • 1.1.5. Estimates and forecast timeline
  • 1.2. Research Methodology
  • 1.3. Information Procurement
    • 1.3.1. Purchased database
    • 1.3.2. GVR's internal database
    • 1.3.3. Secondary sources
    • 1.3.4. Primary research
    • 1.3.5. Details of primary research
      • 1.3.5.1. Data for primary interviews in North America
      • 1.3.5.2. Data for primary interviews in Europe
      • 1.3.5.3. Data for primary interviews in Asia Pacific
      • 1.3.5.4. Data for primary interviews in Latin America
      • 1.3.5.5. Data for Primary interviews in MEA
  • 1.4. Information or Data Analysis
    • 1.4.1. Data analysis models
  • 1.5. Market Formulation & Validation
  • 1.6. Model Details
    • 1.6.1. Commodity flow analysis (Model 1)
    • 1.6.2. Parent Market Analysis
  • 1.7. List of Secondary Sources
  • 1.8. List of Primary Sources
  • 1.9. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Product outlook
    • 2.2.2. Drug Type outlook
    • 2.2.3. Application outlook
    • 2.2.4. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Small Molecule CDMO Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Rise in drug development pipelines
      • 3.2.1.2. Growing reliance on CDMOS for cost-effective and specialized manufacturing services.
      • 3.2.1.3. Capacity expansions by CDMOS
      • 3.2.1.4. Technological advancements
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. Growing demand for biologics
      • 3.2.2.2. Complexity and challenges in synthesis of certain small molecules, impacting manufacturing efficiency
  • 3.3. Small Molecule CDMO Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape

Chapter 4. Small Molecule CDMO Market: Product Estimates & Trend Analysis

  • 4.1. Definitions and Scope
    • 4.1.1. Active Pharmaceutical Ingredients (API)
    • 4.1.2. Finished Drug Products
  • 4.2. Product Market Share, 2023 & 2030
  • 4.3. Segment Dashboard
  • 4.4. Global Small Molecule CDMO Market by Product Outlook
  • 4.5. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 4.5.1. Active Pharmaceutical Ingredients (APIs)
      • 4.5.1.1. Market estimates and forecast 2018 to 2030 (USD Million)
    • 4.5.2. Finished Drug Products
      • 4.5.2.1. Market estimates and forecast 2018 to 2030 (USD Million)

Chapter 5. Small Molecule CDMO Market: Drug Type Estimates & Trend Analysis

  • 5.1. Definitions and Scope
    • 5.1.1. Innovators
    • 5.1.2. Generics
  • 5.2. Drug Type Market Share, 2023 & 2030
  • 5.3. Segment Dashboard
  • 5.4. Global Small Molecule CDMO Market by Drug Type Outlook
  • 5.5. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 5.5.1. Innovators
      • 5.5.1.1. Market estimates and forecast 2018 to 2030 (USD Million)
    • 5.5.2. Generics
      • 5.5.2.1. Market estimates and forecast 2018 to 2030 (USD Million)

Chapter 6. Small Molecule CDMO Market: Application Estimates & Trend Analysis

  • 6.1. Definitions and Scope
    • 6.1.1. Oncology
    • 6.1.2. Cardiovascular Disease
    • 6.1.3. Central Nervous System (CNS) Conditions
    • 6.1.4. Autoimmune/Inflammation
    • 6.1.5. Others
  • 6.2. Application Market Share, 2023 & 2030
  • 6.3. Segment Dashboard
  • 6.4. Global Small Molecule CDMO Market by Application Outlook
  • 6.5. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 6.5.1. Oncology
      • 6.5.1.1. Market estimates and forecast 2018 to 2030 (USD Million)
    • 6.5.2. Cardiovascular Disease
      • 6.5.2.1. Market estimates and forecast 2018 to 2030 (USD Million)
    • 6.5.3. Central Nervous System (CNS) Conditions
      • 6.5.3.1. Market estimates and forecast 2018 to 2030 (USD Million)
    • 6.5.4. Autoimmune/Inflammation
      • 6.5.4.1. Market estimates and forecast 2018 to 2030 (USD Million)
    • 6.5.5. Others
      • 6.5.5.1. Market estimates and forecast 2018 to 2030 (USD Million)

Chapter 7. Small Molecule CDMO Market: Regional Estimates & Trend Analysis

  • 7.1. Regional Market Share Analysis, 2023 & 2030
  • 7.2. Regional Market Dashboard
  • 7.3. Global Regional Market Snapshot
  • 7.4. North America
    • 7.4.1. Market Estimates and Forecast, 2018 - 2030 (Revenue, USD Million)
    • 7.4.2. U.S.
      • 7.4.2.1. Key Country Dynamics
      • 7.4.2.2. Competitive Scenario
      • 7.4.2.3. Regulatory Framework
      • 7.4.2.4. U.S. Market Estimates and Forecasts, 2018 - 2030
    • 7.4.3. Canada
      • 7.4.3.1. Key Country Dynamics
      • 7.4.3.2. Competitive Scenario
      • 7.4.3.3. Regulatory Framework
      • 7.4.3.4. Canada Market Estimates and Forecasts, 2018 - 2030
  • 7.5. Europe
    • 7.5.1. UK
      • 7.5.1.1. Key Country Dynamics
      • 7.5.1.2. Competitive Scenario
      • 7.5.1.3. Regulatory Framework
      • 7.5.1.4. UK Market Estimates and Forecasts, 2018 - 2030
    • 7.5.2. Germany
      • 7.5.2.1. Key Country Dynamics
      • 7.5.2.2. Competitive Scenario
      • 7.5.2.3. Regulatory Framework
      • 7.5.2.4. Germany Market Estimates and Forecasts, 2018 - 2030
    • 7.5.3. France
      • 7.5.3.1. Key Country Dynamics
      • 7.5.3.2. Competitive Scenario
      • 7.5.3.3. Regulatory Framework
      • 7.5.3.4. France Market Estimates and Forecasts, 2018 - 2030
    • 7.5.4. Italy
      • 7.5.4.1. Key Country Dynamics
      • 7.5.4.2. Competitive Scenario
      • 7.5.4.3. Regulatory Framework
      • 7.5.4.4. Italy Market Estimates and Forecasts, 2018 - 2030
    • 7.5.5. Spain
      • 7.5.5.1. Key Country Dynamics
      • 7.5.5.2. Competitive Scenario
      • 7.5.5.3. Regulatory Framework
      • 7.5.5.4. Spain Market Estimates and Forecasts, 2018 - 2030
    • 7.5.6. Denmark
      • 7.5.6.1. Key Country Dynamics
      • 7.5.6.2. Competitive Scenario
      • 7.5.6.3. Regulatory Framework
      • 7.5.6.4. Denmark Market Estimates and Forecasts, 2018 - 2030
    • 7.5.7. Sweden
      • 7.5.7.1. Key Country Dynamics
      • 7.5.7.2. Competitive Scenario
      • 7.5.7.3. Regulatory Framework
      • 7.5.7.4. Sweden Market Estimates and Forecasts, 2018 - 2030
    • 7.5.8. Norway
      • 7.5.8.1. Key Country Dynamics
      • 7.5.8.2. Competitive Scenario
      • 7.5.8.3. Regulatory Framework
      • 7.5.8.4. Norway Market Estimates and Forecasts, 2018 - 2030
  • 7.6. Asia Pacific
    • 7.6.1. Japan
      • 7.6.1.1. Key Country Dynamics
      • 7.6.1.2. Competitive Scenario
      • 7.6.1.3. Regulatory Framework
      • 7.6.1.4. Japan Market Estimates and Forecasts, 2018 - 2030
    • 7.6.2. India
      • 7.6.2.1. Key Country Dynamics
      • 7.6.2.2. Competitive Scenario
      • 7.6.2.3. Regulatory Framework
      • 7.6.2.4. India Market Estimates and Forecasts, 2018 - 2030
    • 7.6.3. China
      • 7.6.3.1. Key Country Dynamics
      • 7.6.3.2. Competitive Scenario
      • 7.6.3.3. Regulatory Framework
      • 7.6.3.4. China Market Estimates and Forecasts, 2018 - 2030
    • 7.6.4. South Korea
      • 7.6.4.1. Key Country Dynamics
      • 7.6.4.2. Competitive Scenario
      • 7.6.4.3. Regulatory Framework
      • 7.6.4.4. South Korea Market Estimates and Forecasts, 2018 - 2030
    • 7.6.5. Australia
      • 7.6.5.1. Key Country Dynamics
      • 7.6.5.2. Competitive Scenario
      • 7.6.5.3. Regulatory Framework
      • 7.6.5.4. Australia Market Estimates and Forecasts, 2018 - 2030
    • 7.6.6. Thailand
      • 7.6.6.1. Key Country Dynamics
      • 7.6.6.2. Competitive Scenario
      • 7.6.6.3. Regulatory Framework
      • 7.6.6.4. Thailand Market Estimates and Forecasts, 2018 - 2030
  • 7.7. Latin America
    • 7.7.1. Brazil
      • 7.7.1.1. Key Country Dynamics
      • 7.7.1.2. Competitive Scenario
      • 7.7.1.3. Regulatory Framework
      • 7.7.1.4. Brazil Market Estimates and Forecasts, 2018 - 2030
    • 7.7.2. Mexico
      • 7.7.2.1. Key Country Dynamics
      • 7.7.2.2. Competitive Scenario
      • 7.7.2.3. Regulatory Framework
      • 7.7.2.4. Mexico Market Estimates and Forecasts, 2018 - 2030
    • 7.7.3. Argentina
      • 7.7.3.1. Key Country Dynamics
      • 7.7.3.2. Competitive Scenario
      • 7.7.3.3. Regulatory Framework
      • 7.7.3.4. Argentina Market Estimates and Forecasts, 2018 - 2030
  • 7.8. MEA
    • 7.8.1. South Africa
      • 7.8.1.1. Key Country Dynamics
      • 7.8.1.2. Competitive Scenario
      • 7.8.1.3. Regulatory Framework
      • 7.8.1.4. South Africa Market Estimates and Forecasts, 2018 - 2030
    • 7.8.2. Saudi Arabia
      • 7.8.2.1. Key Country Dynamics
      • 7.8.2.2. Competitive Scenario
      • 7.8.2.3. Regulatory Framework
      • 7.8.2.4. Saudi Arabia Market Estimates and Forecasts, 2018 - 2030
    • 7.8.3. UAE
      • 7.8.3.1. Key Country Dynamics
      • 7.8.3.2. Competitive Scenario
      • 7.8.3.3. Regulatory Framework
      • 7.8.3.4. UAE Market Estimates and Forecasts, 2018 - 2030
    • 7.8.4. Kuwait
      • 7.8.4.1. Key Country Dynamics
      • 7.8.4.2. Competitive Scenario
      • 7.8.4.3. Regulatory Framework
      • 7.8.4.4. Kuwait Market Estimates and Forecasts, 2018 - 2030

Chapter 8. Competitive Landscape

  • 8.1. Market Participant Categorization
    • 8.1.1. Innovators
    • 8.1.2. Market Leaders
    • 8.1.3. Emerging Players
    • 8.1.4. Company Market Share Analysis, 2023
  • 8.2. Company Profiles
    • 8.2.1. Lonza
      • 8.2.1.1. Company overview
      • 8.2.1.2. Financial performance
      • 8.2.1.3. Service benchmarking
      • 8.2.1.4. Strategic initiatives
    • 8.2.2. Catalent, Inc
      • 8.2.2.1. Company overview
      • 8.2.2.2. Financial performance
      • 8.2.2.3. Service benchmarking
      • 8.2.2.4. Strategic initiatives
    • 8.2.3. Thermo Fisher Scientific Inc.
      • 8.2.3.1. Company overview
      • 8.2.3.2. Financial performance
      • 8.2.3.3. Service benchmarking
      • 8.2.3.4. Strategic initiatives
    • 8.2.4. Cambrex Corporation
      • 8.2.4.1. Company overview
      • 8.2.4.2. Financial performance
      • 8.2.4.3. Service benchmarking
      • 8.2.4.4. Strategic initiatives
    • 8.2.5. Bellen Chemistry
      • 8.2.5.1. Company overview
      • 8.2.5.2. Financial performance
      • 8.2.5.3. Service benchmarking
      • 8.2.5.4. Strategic initiatives
    • 8.2.6. Siegfried Holding AG
      • 8.2.6.1. Company overview
      • 8.2.6.2. Financial performance
      • 8.2.6.3. Service benchmarking
      • 8.2.6.4. Strategic initiatives
    • 8.2.7. Recipharm AB
      • 8.2.7.1. Company overview
      • 8.2.7.2. Financial performance
      • 8.2.7.3. Service benchmarking
      • 8.2.7.4. Strategic initiatives
    • 8.2.8. Eurofins Scientific
      • 8.2.8.1. Company overview
      • 8.2.8.2. Financial performance
      • 8.2.8.3. Service benchmarking
      • 8.2.8.4. Strategic initiatives
    • 8.2.9. Aurigene Pharmaceutical Services Ltd.
      • 8.2.9.1. Company overview
      • 8.2.9.2. Financial performance
      • 8.2.9.3. Service benchmarking
      • 8.2.9.4. Strategic initiatives
    • 8.2.10. CordenPharma International
      • 8.2.10.1. Company overview
      • 8.2.10.2. Financial performance
      • 8.2.10.3. Service benchmarking
      • 8.2.10.4. Strategic initiatives

List of Tables

  • Table 1 List of Abbreviation
  • Table 2 North America Small Molecule CDMO market, by region, 2018 - 2030 (USD Million)
  • Table 3 North America Small Molecule CDMO market, by Product, 2018 - 2030 (USD Million)
  • Table 4 North America Small Molecule CDMO market, by Drug Type, 2018 - 2030 (USD Million)
  • Table 5 North America Small Molecule CDMO market, by application, 2018 - 2030 (USD Million)
  • Table 6 U.S. Small Molecule CDMO market, by Product, 2018 - 2030 (USD Million)
  • Table 7 U.S. Small Molecule CDMO market, by Drug Type, 2018 - 2030 (USD Million)
  • Table 8 U.S. Small Molecule CDMO market, by application, 2018 - 2030 (USD Million)
  • Table 9 Canada Small Molecule CDMO market, by Product, 2018 - 2030 (USD Million)
  • Table 10 Canada Small Molecule CDMO market, by Drug Type, 2018 - 2030 (USD Million)
  • Table 11 Canada Small Molecule CDMO market, by application, 2018 - 2030 (USD Million)
  • Table 12 Europe Small Molecule CDMO market, by region, 2018 - 2030 (USD Million)
  • Table 13 Europe Small Molecule CDMO market, by Product, 2018 - 2030 (USD Million)
  • Table 14 Europe Small Molecule CDMO market, by Drug Type, 2018 - 2030 (USD Million)
  • Table 15 Europe Small Molecule CDMO market, by application, 2018 - 2030 (USD Million)
  • Table 16 Germany Small Molecule CDMO market, by Product, 2018 - 2030 (USD Million)
  • Table 17 Germany Small Molecule CDMO market, by Drug Type, 2018 - 2030 (USD Million)
  • Table 18 Germany Small Molecule CDMO market, by application, 2018 - 2030 (USD Million)
  • Table 19 UK Small Molecule CDMO market, by Product, 2018 - 2030 (USD Million)
  • Table 20 UK Small Molecule CDMO market, by Drug Type, 2018 - 2030 (USD Million)
  • Table 21 UK Small Molecule CDMO market, by application, 2018 - 2030 (USD Million)
  • Table 22 France Small Molecule CDMO market, by Product, 2018 - 2030 (USD Million)
  • Table 23 France Small Molecule CDMO market, by Drug Type, 2018 - 2030 (USD Million)
  • Table 24 France Small Molecule CDMO market, by application, 2018 - 2030 (USD Million)
  • Table 25 Italy Small Molecule CDMO market, by Product, 2018 - 2030 (USD Million)
  • Table 26 Italy Small Molecule CDMO market, by Drug Type, 2018 - 2030 (USD Million)
  • Table 27 Italy Small Molecule CDMO market, by application, 2018 - 2030 (USD Million)
  • Table 28 Spain Small Molecule CDMO market, by Product, 2018 - 2030 (USD Million)
  • Table 29 Spain Small Molecule CDMO market, by Drug Type, 2018 - 2030 (USD Million)
  • Table 30 Spain Small Molecule CDMO market, by application, 2018 - 2030 (USD Million)
  • Table 31 Denmark Small Molecule CDMO market, by Product, 2018 - 2030 (USD Million)
  • Table 32 Denmark Small Molecule CDMO market, by Drug Type, 2018 - 2030 (USD Million)
  • Table 33 Denmark Small Molecule CDMO market, by application, 2018 - 2030 (USD Million)
  • Table 34 Sweden Small Molecule CDMO market, by Product, 2018 - 2030 (USD Million)
  • Table 35 Sweden Small Molecule CDMO market, by Drug Type, 2018 - 2030 (USD Million)
  • Table 36 Sweden Small Molecule CDMO market, by application, 2018 - 2030 (USD Million)
  • Table 37 Norway Small Molecule CDMO market, by Product, 2018 - 2030 (USD Million)
  • Table 38 Norway Small Molecule CDMO market, by Drug Type, 2018 - 2030 (USD Million)
  • Table 39 Norway Small Molecule CDMO market, by application, 2018 - 2030 (USD Million)
  • Table 40 Asia Pacific Small Molecule CDMO market, by region, 2018 - 2030 (USD Million)
  • Table 41 Asia Pacific Small Molecule CDMO market, by Product, 2018 - 2030 (USD Million)
  • Table 42 Asia Pacific Small Molecule CDMO market, by Drug Type, 2018 - 2030 (USD Million)
  • Table 43 Asia Pacific Small Molecule CDMO market, by application, 2018 - 2030 (USD Million)
  • Table 44 China Small Molecule CDMO market, by Product, 2018 - 2030 (USD Million)
  • Table 45 China Small Molecule CDMO market, by Drug Type, 2018 - 2030 (USD Million)
  • Table 46 China Small Molecule CDMO market, by application, 2018 - 2030 (USD Million)
  • Table 47 Japan Small Molecule CDMO market, by Product, 2018 - 2030 (USD Million)
  • Table 48 Japan Small Molecule CDMO market, by Drug Type, 2018 - 2030 (USD Million)
  • Table 49 Japan Small Molecule CDMO market, by application, 2018 - 2030 (USD Million)
  • Table 50 India Small Molecule CDMO market, by Product, 2018 - 2030 (USD Million)
  • Table 51 India Small Molecule CDMO market, by Drug Type, 2018 - 2030 (USD Million)
  • Table 52 India Small Molecule CDMO market, by application, 2018 - 2030 (USD Million)
  • Table 53 South Korea Small Molecule CDMO market, by Product, 2018 - 2030 (USD Million)
  • Table 54 South Korea Small Molecule CDMO market, by Drug Type, 2018 - 2030 (USD Million)
  • Table 55 South Korea Small Molecule CDMO market, by application, 2018 - 2030 (USD Million)
  • Table 56 Australia Small Molecule CDMO market, by Product, 2018 - 2030 (USD Million)
  • Table 57 Australia Small Molecule CDMO market, by Drug Type, 2018 - 2030 (USD Million)
  • Table 58 Australia Small Molecule CDMO market, by application, 2018 - 2030 (USD Million)
  • Table 59 Thailand Small Molecule CDMO market, by Product, 2018 - 2030 (USD Million)
  • Table 60 Thailand Small Molecule CDMO market, by Drug Type, 2018 - 2030 (USD Million)
  • Table 61 Thailand Small Molecule CDMO market, by application, 2018 - 2030 (USD Million)
  • Table 62 Latin America Small Molecule CDMO market, by Product, 2018 - 2030 (USD Million)
  • Table 63 Latin America Small Molecule CDMO market, by Drug Type, 2018 - 2030 (USD Million)
  • Table 64 Latin America Small Molecule CDMO market, by application, 2018 - 2030 (USD Million)
  • Table 65 Brazil Small Molecule CDMO market, by Product, 2018 - 2030 (USD Million)
  • Table 66 Brazil Small Molecule CDMO market, by Drug Type, 2018 - 2030 (USD Million)
  • Table 67 Brazil Small Molecule CDMO market, by application, 2018 - 2030 (USD Million)
  • Table 68 Mexico Small Molecule CDMO market, by Product, 2018 - 2030 (USD Million)
  • Table 69 Mexico Small Molecule CDMO market, by Drug Type, 2018 - 2030 (USD Million)
  • Table 70 Mexico Small Molecule CDMO market, by application, 2018 - 2030 (USD Million)
  • Table 71 Argentina Small Molecule CDMO market, by Product, 2018 - 2030 (USD Million)
  • Table 72 Argentina Small Molecule CDMO market, by Drug Type, 2018 - 2030 (USD Million)
  • Table 73 Argentina Small Molecule CDMO market, by application, 2018 - 2030 (USD Million)
  • Table 74 MEA Small Molecule CDMO market, by region, 2018 - 2030 (USD Million)
  • Table 75 MEA Small Molecule CDMO market, by Product, 2018 - 2030 (USD Million)
  • Table 76 MEA Small Molecule CDMO market, by Drug Type, 2018 - 2030 (USD Million)
  • Table 77 MEA Small Molecule CDMO market, by application, 2018 - 2030 (USD Million)
  • Table 78 South Africa Small Molecule CDMO market, by Product, 2018 - 2030 (USD Million)
  • Table 79 South Africa Small Molecule CDMO market, by Drug Type, 2018 - 2030 (USD Million)
  • Table 80 South Africa Small Molecule CDMO market, by application, 2018 - 2030 (USD Million)
  • Table 81 Saudi Arabia Small Molecule CDMO market, by Product, 2018 - 2030 (USD Million)
  • Table 82 Saudi Arabia Small Molecule CDMO market, by Drug Type, 2018 - 2030 (USD Million)
  • Table 83 Saudi Arabia Small Molecule CDMO market, by application, 2018 - 2030 (USD Million)
  • Table 84 UAE Small Molecule CDMO market, by Product, 2018 - 2030 (USD Million)
  • Table 85 UAE Small Molecule CDMO market, by Drug Type, 2018 - 2030 (USD Million)
  • Table 86 UAE Small Molecule CDMO market, by application, 2018 - 2030 (USD Million)
  • Table 87 Kuwait Small Molecule CDMO market, by Product, 2018 - 2030 (USD Million)
  • Table 88 Kuwait Small Molecule CDMO market, by Drug Type, 2018 - 2030 (USD Million)
  • Table 89 Kuwait Small Molecule CDMO market, by application, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Primary interviews in North America
  • Fig. 5 Primary interviews in Europe
  • Fig. 6 Primary interviews in APAC
  • Fig. 7 Primary interviews in Latin America
  • Fig. 8 Primary interviews in MEA
  • Fig. 9 Market research approaches
  • Fig. 10 QFD modeling for market share assessment
  • Fig. 11 Market formulation & validation
  • Fig. 12 Small Molecule CDMO market: market outlook
  • Fig. 13 Small Molecule CDMO competitive insights
  • Fig. 14 Parent market outlook
  • Fig. 15 Related/ancillary market outlook
  • Fig. 16 Industry value chain analysis
  • Fig. 17 Small Molecule CDMO market driver impact
  • Fig. 18 Small Molecule CDMO market restraint impact
  • Fig. 19 Small Molecule CDMO market: Product movement analysis
  • Fig. 20 Small Molecule CDMO market: Product outlook and key takeaways
  • Fig. 21 Active Pharmaceutical Ingredients (API) market estimates and forecast, 2018 - 2030
  • Fig. 22 Finished Drug Products estimates and forecast, 2018 - 2030
  • Fig. 23 Small Molecule CDMO Market: Drug Type Movement Analysis
  • Fig. 24 Small Molecule CDMO market: Drug Type outlook and key takeaways
  • Fig. 25 Innovators market estimates and forecast, 2018 - 2030
  • Fig. 26 Generics market estimates and forecast, 2018 - 2030
  • Fig. 27 Small Molecule CDMO market: application movement analysis
  • Fig. 28 Small Molecule CDMO market: application outlook and key takeaways
  • Fig. 29 Oncology market estimates and forecast, 2018 - 2030
  • Fig. 30 Cardiovascular Disease market estimates and forecast, 2018 - 2030
  • Fig. 31 Central Nervous System (CNS) Conditions market estimates and forecast, 2018 - 2030
  • Fig. 32 Autoimmune/Inflammation market estimates and forecast, 2018 - 2030
  • Fig. 33 Other market estimates and forecast, 2018 - 2030
  • Fig. 34 Global Small Molecule CDMO market: Regional movement analysis
  • Fig. 35 Global Small Molecule CDMO market: Regional outlook and key takeaways
  • Fig. 36 North America
  • Fig. 37 North America market estimates and forecast, 2018 - 2030
  • Fig. 38 U.S.
  • Fig. 39 U.S. market estimates and forecast, 2018 - 2030
  • Fig. 40 Canada
  • Fig. 41 Canada market estimates and forecast, 2018 - 2030
  • Fig. 42 Europe
  • Fig. 43 Europe market estimates and forecast, 2018 - 2030
  • Fig. 44 UK
  • Fig. 45 UK market estimates and forecast, 2018 - 2030
  • Fig. 46 Germany
  • Fig. 47 Germany market estimates and forecast, 2018 - 2030
  • Fig. 48 France
  • Fig. 49 France market estimates and forecast, 2018 - 2030
  • Fig. 50 Italy
  • Fig. 51 Italy market estimates and forecast, 2018 - 2030
  • Fig. 52 Spain
  • Fig. 53 Spain market estimates and forecast, 2018 - 2030
  • Fig. 54 Denmark
  • Fig. 55 Denmark market estimates and forecast, 2018 - 2030
  • Fig. 56 Sweden
  • Fig. 57 Sweden market estimates and forecast, 2018 - 2030
  • Fig. 58 Norway
  • Fig. 59 Norway market estimates and forecast, 2018 - 2030
  • Fig. 60 Asia Pacific
  • Fig. 61 Asia Pacific market estimates and forecast, 2018 - 2030
  • Fig. 62 China
  • Fig. 63 China market estimates and forecast, 2018 - 2030
  • Fig. 64 Japan
  • Fig. 65 Japan market estimates and forecast, 2018 - 2030
  • Fig. 66 India
  • Fig. 67 India market estimates and forecast, 2018 - 2030
  • Fig. 68 Thailand
  • Fig. 69 Thailand market estimates and forecast, 2018 - 2030
  • Fig. 70 South Korea
  • Fig. 71 South Korea market estimates and forecast, 2018 - 2030
  • Fig. 72 Australia
  • Fig. 73 Australia market estimates and forecast, 2018 - 2030
  • Fig. 74 Latin America
  • Fig. 75 Latin America market estimates and forecast, 2018 - 2030
  • Fig. 76 Brazil
  • Fig. 77 Brazil market estimates and forecast, 2018 - 2030
  • Fig. 78 Mexico
  • Fig. 79 Mexico market estimates and forecast, 2018 - 2030
  • Fig. 80 Argentina
  • Fig. 81 Argentina market estimates and forecast, 2018 - 2030
  • Fig. 82 Middle East and Africa
  • Fig. 83 Middle East and Africa market estimates and forecast, 2018 - 2030
  • Fig. 84 South Africa
  • Fig. 85 South Africa market estimates and forecast, 2018 - 2030
  • Fig. 86 Saudi Arabia
  • Fig. 87 Saudi Arabia market estimates and forecast, 2018 - 2030
  • Fig. 88 UAE
  • Fig. 89 UAE market estimates and forecast, 2018 - 2030
  • Fig. 90 Kuwait
  • Fig. 91 Kuwait market estimates and forecast, 2018 - 2030
  • Fig. 92 Market share of key market players - Small Molecule CDMO market